Jane Street’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Jane Street’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-16,700	Closed	-$402K	–	10009
2023 Q1	$402K	Sell	16,700 -37,900	-69%	-$476K	﹤0.01%	6701
2022 Q4	$577K	Buy	54,600 +40,900	+299%	+$330K	﹤0.01%	5876
2022 Q3	$62K	Buy	+13,700	New	+$62.4K	﹤0.01%	8856
2022 Q1	–	Sell	-55,200	Closed	-$310K	–	11336
2021 Q4	$310K	Sell	55,200 -27,000	-33%	-$171K	﹤0.01%	8109
2021 Q3	$526K	Sell	82,200 -33,700	-29%	-$217K	﹤0.01%	7185
2021 Q2	$977K	Buy	+115,900	New	+$935K	﹤0.01%	5895
2020 Q3	–	Sell	-11,500	Closed	-$162K	–	8188
2020 Q2	$162K	Buy	+11,500	New	+$145K	﹤0.01%	6502

Other funds holding PRVB

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Jane Street's PRVB Position: Q2 2023 in Review

Jane Street sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 176,649 shares — an estimated $4.26M sold.

Jane Street first reported a position in PRVB in Q1 2020 and held it in 12 quarters. The position peaked at $4.26M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Jane Street reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Jane Street sold 176,649 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $4.26M.
Jane Street first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
Jane Street's Provention Bio, Inc. Common Stock position peaked at $4.26M in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.